-
1.发明授权Intermediates for preparing dual-acting benzyl triazole antihypertensive agents having angiotensin II type I receptor antagonist activity and neprilysin-inhibition activity 有权用于制备具有血管紧张素II I型受体拮抗剂活性和去甲肾上腺素抑制活性的双作用苄基三唑抗高血压药的中间体公开(公告)号：US08895755B2
公开(公告)日：2014-11-25
申请号：US14035042
申请日：2013-09-24
申请人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
发明人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
IPC分类号： C07D249/08 , C07D513/04 , C07D213/89 , C07D233/64 , C07D233/70 , A61K31/4188 , C07D233/68 , C07D513/14 , C07D231/14 , C07D233/90 , A61K31/4196 , C07D403/10 , C07D401/12 , C07D213/64 , C07D207/46 , A61K45/00 , C07D255/02 , A61K31/415 , A61K31/4412 , A61K31/417
CPC分类号： C07D233/70 , A61K31/415 , A61K31/4164 , A61K31/417 , A61K31/4188 , A61K31/4196 , A61K31/4412 , A61K45/00 , A61K45/06 , C07D207/36 , C07D207/46 , C07D213/64 , C07D213/89 , C07D231/14 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D255/02 , C07D401/12 , C07D403/10 , C07D513/04 , C07D513/14
摘要： The invention is directed to intermediates for preparing compounds having the formula: wherein: Ar, X, R3 ,and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity.
摘要翻译： 本发明涉及用于制备具有下式的化合物的中间体：其中：Ar，X，R 3和R 5-7如说明书中所定义，及其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。
-
公开(公告)号：US20140024835A1
公开(公告)日：2014-01-23
申请号：US14035042
申请日：2013-09-24
申请人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
发明人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
IPC分类号： C07D403/10 , C07D233/64 , C07D213/64 , C07D231/14 , C07D249/08 , C07D233/68 , C07D233/70
CPC分类号： C07D233/70 , A61K31/415 , A61K31/4164 , A61K31/417 , A61K31/4188 , A61K31/4196 , A61K31/4412 , A61K45/00 , A61K45/06 , C07D207/36 , C07D207/46 , C07D213/64 , C07D213/89 , C07D231/14 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D255/02 , C07D401/12 , C07D403/10 , C07D513/04 , C07D513/14
摘要： The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 本发明涉及具有下式的化合物：其中：Ar，r，Y，Z，Q，W，X和R5-7如说明书中所定义，及其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 本发明还涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US09198899B2
公开(公告)日：2015-12-01
申请号：US14132391
申请日：2013-12-18
申请人： Paul Allegretti , Seok-Ki Choi , Paul R. Fatheree , Roland Gendron , Ryan Hudson , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
发明人： Paul Allegretti , Seok-Ki Choi , Paul R. Fatheree , Roland Gendron , Ryan Hudson , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
IPC分类号： C07D235/08 , A61K31/4184 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/12 , A61K31/4439 , A61K31/5377 , A61K45/06 , C07D405/10
CPC分类号： A61K31/4184 , A61K31/4439 , A61K31/5377 , A61K45/06 , C07D235/08 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/10 , C07D405/12
摘要： The invention is directed to compounds having the formula: wherein: Ar, r, n, X, R2-3 and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 本发明涉及具有下式的化合物：其中：Ar，r，n，X，R2-3和R5-7如说明书中所定义，及其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 本发明还涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US08637676B2
公开(公告)日：2014-01-28
申请号：US12156695
申请日：2008-06-04
申请人： Paul Allegretti , Seok-Ki Choi , Paul R. Fatheree , Roland Gendron , Ryan Hudson , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
发明人： Paul Allegretti , Seok-Ki Choi , Paul R. Fatheree , Roland Gendron , Ryan Hudson , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
IPC分类号： A61K31/4184 , C07D235/08
CPC分类号： A61K31/4184 , A61K31/4439 , A61K31/5377 , A61K45/06 , C07D235/08 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/10 , C07D405/12
摘要： The invention is directed to compounds having the formula: wherein: Ar, r, n, X, R2-3 and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 本发明涉及具有下式的化合物：其中：Ar，r，n，X，R2-3和R5-7如说明书中所定义，及其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 本发明还涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US08268851B2
公开(公告)日：2012-09-18
申请号：US12645349
申请日：2009-12-22
申请人： Somasekhar Bhamidipati , Hui Li , Rajinder Singh , Vanessa Taylor , Jeffrey Clough , Darren McMurtrie
发明人： Somasekhar Bhamidipati , Hui Li , Rajinder Singh , Vanessa Taylor , Jeffrey Clough , Darren McMurtrie
IPC分类号： A01N43/54 , A61K31/505
CPC分类号： C07D239/48
摘要： The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
摘要翻译： 本发明包括具有式I的化合物和使用这些化合物的组合物和方法用于治疗JAK途径的调节或JAK激酶，特别是JAK3的抑制在治疗上有用的条件。
-
公开(公告)号：US20110281925A1
公开(公告)日：2011-11-17
申请号：US13191100
申请日：2011-07-26
申请人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
发明人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
IPC分类号： A61K31/415 , A61P9/12 , C07D231/12
CPC分类号： C07D233/70 , A61K31/415 , A61K31/4164 , A61K31/417 , A61K31/4188 , A61K31/4196 , A61K31/4412 , A61K45/00 , A61K45/06 , C07D207/36 , C07D207/46 , C07D213/64 , C07D213/89 , C07D231/14 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D255/02 , C07D401/12 , C07D403/10 , C07D513/04 , C07D513/14
摘要： The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 本发明涉及具有下式的化合物：其中：Ar，r，Y，Z，Q，W，X和R5-7如说明书中所定义，及其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 本发明还涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US20110092551A1
公开(公告)日：2011-04-21
申请号：US12974210
申请日：2010-12-21
申请人： Paul ALLEGRETTI , Seok-Ki CHOI , Roland GENDRON , Paul R. FATHEREE , Keith JENDZA , Robert Murray McKINNELL , Darren McMURTRIE , Brooke OLSON
发明人： Paul ALLEGRETTI , Seok-Ki CHOI , Roland GENDRON , Paul R. FATHEREE , Keith JENDZA , Robert Murray McKINNELL , Darren McMURTRIE , Brooke OLSON
IPC分类号： A61K31/4196 , G01N33/53 , C07D233/64 , C07D257/04 , C07D231/12 , C07D249/08 , C07D211/76 , A61K31/4164 , A61K31/415 , A61K31/41 , A61K31/4412 , A61P9/12
CPC分类号： C07D233/70 , A61K31/415 , A61K31/4164 , A61K31/417 , A61K31/4188 , A61K31/4196 , A61K31/4412 , A61K45/00 , A61K45/06 , C07D207/36 , C07D207/46 , C07D213/64 , C07D213/89 , C07D231/14 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D255/02 , C07D401/12 , C07D403/10 , C07D513/04 , C07D513/14
摘要： The invention is directed to compounds having the formula: wherein: Ar, r, R2-3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 本发明涉及具有下式的化合物：其中：Ar，r，R2-3，X和R5-7如说明书中所定义，及其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 本发明还涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US20060122123A1
公开(公告)日：2006-06-08
申请号：US11184429
申请日：2005-07-18
IPC分类号： A61K38/05 , A61K31/4709 , A61K31/4025 , A61K31/401 , C07K5/06 , C07D403/02
CPC分类号： C07K5/0827 , A61K38/00 , C07F9/572 , C07F9/65583 , C07K5/06191 , C07K5/0808
摘要： The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
摘要翻译： 本发明涉及磷取代的抗病毒抑制化合物，含有这些化合物的组合物，以及包括施用这些化合物的治疗方法以及可用于制备这些化合物的方法和中间体。
-
公开(公告)号：US09150514B2
公开(公告)日：2015-10-06
申请号：US14521689
申请日：2014-10-23
申请人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
发明人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
IPC分类号： A61K31/4174 , A61K31/415 , A61K31/4196 , A61K31/4412 , C07D213/89 , C07D213/64 , C07D231/14 , C07D233/64 , C07D233/68 , C07D233/70 , C07D233/90 , C07D249/08 , C07D401/12 , C07D403/10 , C07D513/04 , C07D513/14 , A61K31/417 , A61K31/4188 , A61K45/00 , C07D207/46 , C07D255/02 , A61K31/4164 , A61K45/06 , C07D207/36
CPC分类号： C07D233/70 , A61K31/415 , A61K31/4164 , A61K31/417 , A61K31/4188 , A61K31/4196 , A61K31/4412 , A61K45/00 , A61K45/06 , C07D207/36 , C07D207/46 , C07D213/64 , C07D213/89 , C07D231/14 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D255/02 , C07D401/12 , C07D403/10 , C07D513/04 , C07D513/14
摘要： The invention is directed to methods for treating hypertension or heart failure using compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. In particular embodiments, the invention uses compounds having formula IIIa, IVa, Va: These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity.
摘要翻译： 本发明涉及使用具有下式的化合物治疗高血压或心力衰竭的方法：其中：Ar，r，Y，Z，Q，W，X和R5-7如本说明书中所定义，及其药学上可接受的盐 。 在具体实施方案中，本发明使用具有式IIIa，IVa，Va的化合物：这些化合物具有AT1受体拮抗剂活性和尿丙氨酸抑制活性。
-
公开(公告)号：US20130096162A1
公开(公告)日：2013-04-18
申请号：US13692538
申请日：2012-12-03
申请人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
发明人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
IPC分类号： C07D513/14 , A61K31/4196 , A61K31/4188 , A61K31/417 , A61K45/00 , C07D213/89 , C07D255/02 , C07D207/46 , C07D231/14 , A61K31/4412 , A61K31/415
CPC分类号： C07D233/70 , A61K31/415 , A61K31/4164 , A61K31/417 , A61K31/4188 , A61K31/4196 , A61K31/4412 , A61K45/00 , A61K45/06 , C07D207/36 , C07D207/46 , C07D213/64 , C07D213/89 , C07D231/14 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D255/02 , C07D401/12 , C07D403/10 , C07D513/04 , C07D513/14
摘要： The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
-
-
-
-
-
-
-
-
-
搜索结果
34 条记录 (耗时 0.046 秒)
